Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 11.2% in November

Posted by Linda Flegge on Dec 4th, 2024

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 144,000 shares, a growth of 11.2% from the October 31st total of 129,500 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is presently 9.6 days. Currently, 0.5% of the company’s stock are sold short.

Analysts Set New Price Targets

EPRX has been the topic of a number of research reports. Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Check Out Our Latest Stock Report on Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX opened at $3.25 on Wednesday. The firm has a market cap of $88.66 million and a P/E ratio of -4.51. The stock’s 50-day moving average is $2.83 and its two-hundred day moving average is $2.72. Eupraxia Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $5.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC acquired a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,000 shares of the company’s stock, valued at approximately $34,000.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.